drugset
drugset / Trial / NCT07422142

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Gastrodin Injection in Healthy Chinese Subjects

NCT07422142 ↗

Phase 1 Not yet recruiting 54 enrolled Kunming Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a single-center, double-blind study to evaluate the safety, tolerability, pharmacokinetics of Gastrodin Injection in healthy Subjects

Timeline

Start
2026-03-01
Primary completion
2026-09-30
Completion
2026-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Gastrodin Small molecule 300 mg Intravenous
Subject Gastrodin Small molecule 600 mg Intravenous
Subject Gastrodin Small molecule 900 mg Intravenous
Subject Gastrodin Small molecule 1200 mg Intravenous
Subject Gastrodin Small molecule 1800 mg Intravenous

Indications

delirium